Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Amphastar Pharmaceuticals, Inc. (AMPH) - free report >>
Cirrus Logic, Inc. (CRUS) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amphastar Pharmaceuticals, Inc. (AMPH) - free report >>
Cirrus Logic, Inc. (CRUS) - free report >>
Image: Bigstock
New Strong Sell Stocks for May 29th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Amphastar Pharmaceuticals, Inc. (AMPH - Free Report) is a specialty pharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 36.5% downward over the last 30 days.
Dycom Industries, Inc. (DY - Free Report) is a provider of specialty contracting services. The Zacks Consensus Estimate for its current year earnings has been revised 16.5% downward over the last 30 days.
BGC Partners, Inc. is a brokerage company. The Zacks Consensus Estimate for its current year earnings has been revised 1.5% downward over the last 30 days.
Cirrus Logic, Inc. (CRUS - Free Report) is a fabless semiconductor company. The Zacks Consensus Estimate for its current year earnings has been revised 19.8% downward over the last 30 days.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN - Free Report) is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 10.8% downward over the last 30 days.
View the entire Zacks Rank #5 List.